A Phase I/II Study of the HDAC Inhibitor LBH589 in Combination with the mTOR Inhibitor Everolimus (RAD001) in Metastatic Renal Cell Carcinoma
Description: 

Phase I of this study will evaluate the safety and tolerability of three possible dose levels. The two drug regimen will be given as a three week cycle. A minimum of 6 patients will be treated at each dose level. Dose level toxicities will be evaluated to determine dose modifications and the recommended dose level for Phase II.
Phase II will evaluate the effects of this drug combination on the progression free survival in patients with metastatic RCC.

Study Number: 

I 146308

Phase: 
I/II
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01037257

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.